Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (108)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (277)
  2. Genitourinary Oncology Service (277)
  3. Solid Tumor Oncology Division (277)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Department of Pathology and Laboratory Medicine (43)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (13)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (17)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (25)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (277)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer and BRCA1/2 gene alterations: Final analysis from the randomized phase 3 MAGNITUDE trial
    Journal Article

    Rathkopf, D. E.; Roubaud, G.; Chi, K. N.; Efstathiou, E.; Attard, G.; Olmos, D.; Small, E. J.; Saad, M.; Castro, E.; Kim, W.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: Final overall survival analysis for the Phase 3 MAGNITUDE trial
    Journal Article

    Chi, K. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S.; Efstathiou, E.; Roubaud, G.; Small, E. J.; Gomes, A. P. D.; Rathkopf, D. E.; more...
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
    Meeting Abstract

    Attard, G.; Agarwal, N.; Graff, J. N.; Sandhu, S.; Efstathiou, E.; Özgüroğlu, M.; de Santana Gomes, A. J. P.; Vianna, K. C. M.; Luo, H.; Cheng, H. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • National cancer system characteristics and prostate cancer outcomes: An analysis of global data
    Journal Article

    Dee, E. C.; Iyengar, R.; Narayan, A.; Feliciano, E. J. G.; Wu, J. F.; Ho, F. D. V.; Ng, K.; Willmann, J.; Cabaero, M. L. L.; Tan, A. K. N. G.; more...
    Prostate (2025)

    Fulltext@MSK | Save
  • rechARge: A randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC
    Journal Article

    Chi, K. N.; McKay, R. R.; Sandhu, S.; Arranz, J. A.; Barthélémy, P.; Hadaschik, B.; Matsubara, N.; Shore, N. D.; Ye, D.; Cascella, T.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer
    Journal Article

    Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
    Journal of Immunotherapy and Precision Oncology (2025)

    Fulltext@MSK | Save
  • High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes
    Journal Article

    Sharifi, M. N.; Sperger, J. M.; Taylor, A. K.; Tippins, K. E.; Reese, S. R.; Carreno, V.; Kaufmann, K. R.; Chang, A. H.; Nunamaker, L. A.; Linebarger, C.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer
    Meeting Abstract

    McManus, H. D.; Howard, L.; Crowell, K. A.; Hyslop, T.; Autio, K. A.; Rathkopf, D.; Dreicer, R.; Chi, K. N.; Ong, M.; Mateo, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC)
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D.; Runcie, K.; Zhang, T.; Gotto, G.; Merseburger, A. S.; Dos Santos, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
    Editorial

    Chi, K. N.; Rathkopf, D.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Pereira de Santana Gomes, A. J.; Roubaud, G.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save